Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Express Scripts
Dow
McKesson

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR PROMACTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Promacta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00643929 ↗ LENS - Long-term Eltrombopag Observational Study Completed GlaxoSmithKline 2007-02-01 A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.
NCT00909363 ↗ Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Terminated Novartis Pharmaceuticals Phase 2 2009-06-01 The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
NCT00909363 ↗ Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Terminated Weill Medical College of Cornell University Phase 2 2009-06-01 The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Promacta

Condition Name

Condition Name for Promacta
Intervention Trials
Thrombocytopenia 9
Leukemia 4
Hepatitis C 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Promacta
Intervention Trials
Thrombocytopenia 16
Leukemia 8
Preleukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Promacta

Trials by Country

Trials by Country for Promacta
Location Trials
United States 52
Italy 13
Canada 10
Germany 10
Brazil 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Promacta
Location Trials
Texas 7
New York 6
Maryland 5
California 4
North Carolina 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Promacta

Clinical Trial Phase

Clinical Trial Phase for Promacta
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Promacta
Clinical Trial Phase Trials
Completed 11
Terminated 8
Active, not recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Promacta

Sponsor Name

Sponsor Name for Promacta
Sponsor Trials
GlaxoSmithKline 15
M.D. Anderson Cancer Center 6
Novartis Pharmaceuticals 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Promacta
Sponsor Trials
Other 29
Industry 26
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Medtronic
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.